July 1st 2025
New clinical trials reveal PER-001 as a groundbreaking treatment for glaucoma and diabetic retinopathy, showing significant vision improvements and safety.
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Practical Approaches to Modern Dry Eye Treatment and Management
June 25, 2025
Register Now!
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)
View More
Retina Specialists: Join us in Long Beach
July 31, 2025 - August 2, 2025
Register Now!
SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application
View More
3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
September 6, 2025
Register Now!
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D
View More
EyeCon 2025
September 26-27, 2025
Register Now!
Optometrists: Earn COPE CE Credits in Portland or Virtually
October 16-17, 2025
Register Now!
Join us at The Ophthalmology Meeting in Orlando this October
October 18, 2025
Register Now!
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Expert Perspectives on Technological Advances in Cataract Surgery
View More
Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy
View More
Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy
View More
(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs
View More
(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention
View More
(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?
View More
Understanding the costs of genetic testing for ocular disease
November 25th 2014An article recently published in Current Opinion in Ophthalmology looked to help eyecare practitioners understand the costs of genetic testing in ocular disease, the complexities of insurance coverage, and its impact on the availability of genetic testing.
FDA approves VisionCare telescope implant for AMD
November 25th 2014The U.S. Food and Drug Administration recently approved VisionCare Ophthalmic Technologies’ Implantable Miniature Telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older.
AAOphth’s IRIS database now used by one third of ECPs
November 25th 2014The American Academy of Ophthalmology says that close to one-third of the nation's eye physicians and surgeons are participating in the Intelligent Research In Sight (IRIS) Registry, which is the first comprehensive database of eye diseases and conditions in the United States.
Current views on genetic testing for AMD
October 24th 2014Genetic testing in AMD is a relatively new focus for optometrists and an important one to ensure that we are getting a complete view of our patients’ risk for developing advanced AMD. Although we are making some progress, we still have work to do to gain a better understanding of how to incorporate its use into clinical practice.
Ohr plans Phase III trials on squalamine eye drops for wet AMD
October 17th 2014Ohr Pharmaceutical recently announced details of the planned Phase III registration trials for squalamine eye drops (OHR-102) in the treatment of wet age-related macular degeneration (AMD), which are being designed based on guidance provided by the U.S. Food and Drug Administration (FDA) at a recent "end of Phase II" meeting.
Experiencing retinal detachment as an OD
October 15th 2014When the retina in my left eye detached in early October 2013, I was on a tour bus, somewhere between Canter’s Deli and Griffith Observatory, in Los Angeles. There was a series of flashes, like warning flares, and then a black tide, an oil slick of a blind spot that started down and to the left and crept toward the center of my vision, arcs of lightning heralding its advance. I knew what was happening, but I didn’t want to believe it.
AMD supplements may accelerate the disease in some people
September 5th 2014Nutritional supplements meant to slow the progression of age-related macular degeneration (AMD) may actually accelerate the disease in people with certain genotypes, according to research recently presented at the American Society of Retina Specialists annual meeting.
Delayed or immediate laser treatment for DME yield similar results
September 5th 2014According to research recently presented at the American Society of Retina Specialists annual meeting, focal or grid laser treatment that coincides with the initiation of intravitreal ranibizumab for the treatment of diabetic macular edema (DME) shows results no better than when laser treatment is deferred for 24 weeks or more.
Oraya Therapeutics receives grant to study wet AMD treatment
September 5th 2014The National Institutes of Health recently awarded a $215,000 Small Business Technology Transfer Grant to Oraya Therapeutics to investigate how its therapy and gold nanoparticles affect the treatment of wet age-related macular degeneration (AMD).
Continuing the conversation on mesozeaxanthin
August 26th 2014I want to thank the Macular Pigment Research Group (MPRG), Waterford, Ireland for responding to my assertion that mesozeaxanthin (MZ) in supplement form, even if it was scientifically possible to study alone as a supplement, has not proven as of yet to be necessary to build central foveal macular pigment, improve cone visual function, or uniquely protect the retina from age-related macular degeneration (AMD).
Rebutting mesozeaxanthin findings
August 19th 2014We read with interest, and some surprise, Dr. Stuart Richer’s article in Optometry Times entitled “The third carotenoid-mesozeaxanthin (Z-RS) and who needs to consume it.” In this article, Dr. Richer concludes that “simple proclamations...are misleading,” and we concur with his conclusion in this regard
AMD patients respond to aflibercept treatment
August 14th 2014A study recently published in the British Journal of Ophthalmology found that patients with exudative age-related macular degeneration (AMD) who were incomplete responders to multiple ranibizumab injections (Lucentis, Genentech) saw improvements with aflibercept (Eylea, Regeneron) treatment.
Intravitreal injections by optometrists?
August 1st 2014Our profession has had to fight for the privilege of caring for our patients with ocular disease. With optometry as a legislated profession, these battles have occurred in every state and, as a result, optometric practice acts vary widely. Ophthalmology does not have to endure such travails. Ophthalmologists can do pretty much whatever is in their purview, as is their right.